Finvest
KNSA Biotechnology · Commercial-stage biotech · Cardio inflammation · Rare disease · Thesis updated July 1, 2026

ARCALYST is working, concentration still bites

01 Running thesis

Fast growth, narrow base

Kiniksa is executing very well right now. ARCALYST sales reached $214.3 million in Q1 2026, up from $137.8 million in Q1 2025. The company also lifted full-year 2026 ARCALYST guidance to $930 million to $945 million after a record quarter for new prescribers and new patient enrollments.

That growth gives Kiniksa a cleaner story than many biotech firms. It already has a large approved product, and that product is funding the company. The cash can pay for more commercial work, a targeted direct-to-consumer ad campaign, and trials for KPL-387 and KPL-1161.

The bear case has not gone away. ARCALYST is the whole revenue base. The pipeline is also aimed at the same biology and the same core market, recurrent pericarditis. If a better or easier treatment changes the market, Kiniksa has little backup outside this franchise.

The stock also has a price question. The operating story is strong, but a buyer is paying for continued ARCALYST growth plus future pipeline success. That makes each data point on patient starts, payer coverage, gross-to-net discounts, and competition matter.

Apr 2026▲Kiniksa raised full-year 2026 ARCALYST revenue guidance to $930 million to $945 million after Q1 revenue of $214.3 million and record new prescriber growth.
Apr 2026▲The Q1 2026 10-Q showed the FDA accepted the ARCALYST manufacturing transfer sBLA and assigned a June 19, 2026 target decision date. Kiniksa also moved up its expected KPL-387 Phase 3 start to by year-end 2026.
Feb 2026▲Kiniksa reported 2025 ARCALYST revenue of $677.6 million and its first full year of profitability, with $59.0 million of net income.
Feb 2026→The company sharpened focus on the IL-1 franchise, while adding a clearer future competition risk from Eli Lilly and Ventyx.
Oct 2025▲ARCALYST Q3 2025 revenue reached $180.9 million, and management raised 2025 guidance to $670 million to $675 million.
Oct 2025▲KPL-387 received FDA Orphan Drug Designation for pericarditis, adding support to the next-generation pipeline case.
Jul 2025▲Kiniksa reported $156.8 million of Q2 2025 ARCALYST revenue and raised 2025 guidance to $625 million to $640 million.
Jul 2025▲The company began recruiting in the Phase 2 portion of the pivotal KPL-387 trial, moving its follow-on drug from plan to active clinical work.
02 Business model

One drug funds the lab

Kiniksa makes money from ARCALYST product sales. ARCALYST treats recurrent pericarditis, a painful swelling around the heart that keeps coming back. The drug blocks IL-1, an inflammation signal in the body.

The model is meant to be self-funding. ARCALYST pays for the sales force, patient support, and the next drugs in the same family. Kiniksa also has an economic arrangement with Regeneron tied to ARCALYST.

This model works best if more doctors keep using ARCALYST and payers keep covering it. In Q1 2026, more than 4,550 prescribers had written ARCALYST since launch, including about 400 new prescribers in the quarter.

Where it can break is clear. If patient starts slow, if co-pay support or discounts pressure net price, or if manufacturing costs rise, the same single product that funds the company can become a bottleneck.

03 Product portfolio

ARCALYST first, follow-ons next

Cash cow

ARCALYST

ARCALYST is the only revenue-generating product. It is approved for recurrent pericarditis and produced $214.3 million of net product revenue in Q1 2026.

Option

ARCALYST in cardiac sarcoidosis

Kiniksa began a collaborative Mayo Clinic study in December 2024 to test ARCALYST in cardiac sarcoidosis. This is an expansion option, not the current revenue driver.

Growth engine

KPL-387

KPL-387 is an IL-1R1 antibody being developed for monthly under-the-skin dosing in recurrent pericarditis. Phase 2 dose-focusing data are expected in the second half of 2026, and Kiniksa expects to start a pivotal Phase 3 trial by the end of 2026.

Option

KPL-1161

KPL-1161 is a pre-clinical, longer-lasting version of KPL-387. Kiniksa wants to begin a Phase 1 trial by the end of 2026, with the goal of possible quarterly dosing.

Steady

Legacy programs

Kiniksa has narrowed the portfolio. Abiprubart development was discontinued, and the mavrilimumab collaboration with Huadong was terminated.

04 Business segments

Revenue is all ARCALYST

ARCALYST net product revenue100%growing fast
Pipeline and other programs0%flat

For the three months ended March 31, 2026, Kiniksa reported $214.3 million of ARCALYST net product revenue. The mix below shows that reported revenue stream at 100%, with pipeline programs at 0% revenue today.

05 Risk factors

What could break the story

Single-product dependence

High impact · High odds

Kiniksa's revenue and profit depend on ARCALYST. A safety issue, label change, supply problem, or payer pushback would hit the whole company, not just one division.

We watchTrack quarterly ARCALYST net revenue versus the 2026 guidance range of $930 million to $945 million.

Same-market pipeline risk

High impact · Medium odds

KPL-387 and KPL-1161 are meant to extend the same IL-1 franchise in recurrent pericarditis. That helps focus spending, but it also means pipeline failure would not diversify the company.

We watchWatch for Phase 2 dose-focusing data from KPL-387 in the second half of 2026 and the start of Phase 3 by year-end 2026.

Manufacturing transfer outcome

Medium impact · Medium odds

Kiniksa submitted a supplemental biologics license application for the ARCALYST manufacturing transfer to Samsung, and the FDA assigned a June 19, 2026 target decision date. The key investor issue is not only approval, but whether the transfer improves cost of goods sold and gross margin.

We watchWatch management's comments on Samsung supply, cost of goods sold, and gross margin in the next earnings update.

Payer and co-pay pressure

Medium impact · Medium odds

ARCALYST growth needs insurance coverage and patient affordability support. Management said co-pay assistance changes in early 2026 affected gross-to-net results, which means revenue can move even when demand is healthy.

We watchWatch gross-to-net commentary, average co-pay support, and any signs of tougher payer rules.

Future oral competition

High impact · Medium odds

The 2025 10-K noted Eli Lilly's planned acquisition of Ventyx, which is developing VTX2735, an oral NLRP3 inhibitor. If an oral drug is effective and safe, some patients and doctors may prefer it over injected IL-1 therapies.

We watchWatch VTX2735 trial updates, Lilly's development plans, and any head-to-head or real-world comparisons.

KPL-387 cannibalization

Medium impact · Medium odds

If KPL-387 works, it could also take patients from ARCALYST because both target recurrent pericarditis. That may still be good for Kiniksa if the new drug has better dosing or economics, but the company has not yet detailed the full commercial plan.

We watchWatch how management positions monthly KPL-387 versus ARCALYST as Phase 3 approaches.
06 Quick answers

In one breath

What does Kiniksa Pharmaceuticals sell?

Kiniksa sells ARCALYST, also called rilonacept, for recurrent pericarditis. Recurrent pericarditis is repeated inflammation around the heart.

Why is ARCALYST so important to Kiniksa?

ARCALYST is Kiniksa's only revenue-generating product. It produced $214.3 million of net product revenue in Q1 2026 and funds the company's commercial work and pipeline.

What are KPL-387 and KPL-1161?

They are follow-on IL-1 drugs being built for recurrent pericarditis. KPL-387 is in clinical testing and may start Phase 3 by the end of 2026, while KPL-1161 is earlier and is designed for a longer dosing gap.

What is the biggest risk for KNSA stock?

The biggest risk is concentration. Kiniksa depends on one drug in one main disease market, while future competitors may try to change how recurrent pericarditis is treated.